CRISPR Therapeutics

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Retrieved on: 
Tuesday, September 3, 2024
HS, CRISPR Therapeutics, Skin, Half-life, Paradigm, RTW, Psoriatic arthritis, Therapy, ARCA, Doctor of Philosophy, PASI, SQ, Disease, Hidradenitis suppurativa, Psoriasis, Axial spondyloarthritis, Ankylosing spondylitis, Investment, Patient, IL-17A, Biotechnology, Pharmaceutical industry

MENLO PARK, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma, Inc. The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market today, September 3, 2024, under the ticker symbol “ORKA”. In addition, Oruka announced the appointment of Samarth Kulkarni, PhD, current Chairman and CEO of CRISPR Therapeutics, as Chairman of Oruka’s Board of Directors.

Key Points: 
  • The combined company will operate under the name Oruka Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Global Market today, September 3, 2024, under the ticker symbol “ORKA”.
  • In addition, Oruka announced the appointment of Samarth Kulkarni, PhD, current Chairman and CEO of CRISPR Therapeutics, as Chairman of Oruka’s Board of Directors.
  • IL-17A/F inhibition has also shown promising efficacy in other diseases such as hidradenitis suppurativa (HS) and axial spondyloarthritis (axSpA).
  • ORKA-002 is designed to provide patients an option with substantially less frequent dosing, while offering similar levels of disease clearance compared to currently marketed agents.

CRISPR Cas9 Market Opportunity & Clinical Trials Market Outlook to 2029: Focus on Approved CRISPR-Cas9 Therapy - Casgevy (Exagamglogene Autotemcel) Therapy Clinical Insight - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 15, 2024
Biotechnology, Genetics, Health, CRISPR Therapeutics, Transcoding, CNS, Cas9, Cancer, Intellia Therapeutics, Anti-transglutaminase antibodies, Beta thalassemia, Statistics, Therapy, CRISPR, Safety, Indication, DSM-IV codes, Research, Cardiomyopathy, Editas Medicine, Medicine, Pharmaceutical industry

The "CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CRISPR Cas9 Market Opportunity & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global landscape of medical therapies is poised for a paradigm shift with the advent of CRISPR/Cas9 technologies.
  • Anticipated to revolutionize the treatment of genetic disorders, cancer, and an array of other diseases, the CRISPR Cas9 market is expected to significantly grow and present vast opportunities in clinical trials and therapeutic applications by 2029.
  • Many of ongoing CRISPR/Cas9 clinical trials have reached late stage of development and it is predicable that they will penetrate into the market in the imminent 5-7 years.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Retrieved on: 
Monday, August 5, 2024
EAP, Kingdom, Senior, ANGPTL3, International development, Moyamoya disease, Sickle cell disease, TCL, Priority review, Congress, Cas9, ALAS1, TDT, Hypertension, Patient, Lymphoid leukemia, MACE, Stem cell, Type 1 diabetes, Therapy, Angiotensin, Immunology, Cardiovascular disease, CRISPR Therapeutics, CRSP, LNP, Cell, Liver, Triglyceride, European, Inflammation, Corporate communication, T1D, AHP, KSA, SLE, Vertex Pharmaceuticals, LPA, Risk, ADC, Clinical trial, CD70, ASCVD, SCD, Partnership, Hypertriglyceridemia, AGT, CD19, CRISPR, Research, Pharmaceutical industry

R&D Expenses: R&D expenses were $80.2 million for the second quarter of 2024, compared to $101.6 million for the second quarter of 2023.

Key Points: 
  • R&D Expenses: R&D expenses were $80.2 million for the second quarter of 2024, compared to $101.6 million for the second quarter of 2023.
  • G&A Expenses: General and administrative expenses were $19.5 million for the second quarter of 2024, compared to $19.0 million for the second quarter of 2023.
  • Collaboration Expense: Collaboration expense, net, was $52.1 million for the second quarter of 2024, compared to $44.6 million for the second quarter of 2023.
  • Net Loss: Net loss was $126.4 million for the second quarter of 2024, compared to a net loss of $77.7 million for the second quarter of 2023.

Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15

Retrieved on: 
Monday, August 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Vaccination, Therapy, WHO, Disease, Sanofi, CRISPR Therapeutics, Bristol Myers Squibb, GSK, CHIM, AstraZeneca, Notifiable disease, Acceleron Pharma, Teva, Safety, J&J, CRISPR, Vaccine, Cold medicine

ILiAD Biotechnologies, LLC (ILiAD), a biotech company developing the most advanced next generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the Company to the Fierce 15 2024 list ( link ), identifying ILiAD as one of the most promising and innovative biotechnology companies in the industry.

Key Points: 
  • ILiAD Biotechnologies, LLC (ILiAD), a biotech company developing the most advanced next generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the Company to the Fierce 15 2024 list ( link ), identifying ILiAD as one of the most promising and innovative biotechnology companies in the industry.
  • Keith Rubin, M.D., ILiAD Chief Executive Officer and Founder remarked, “We are grateful to be recognized as a Fierce 15 company.
  • Fierce Biotech is an internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals.
  • A substantial number of Fierce 15 recipients have also subsequently been acquired by large pharmaceutical companies, including Teva, Sanofi, GSK, Gilead, J&J, Bristol Myers Squibb and Astra Zeneca.

Analysts Hunt for Undervalued Biotech Stocks

Retrieved on: 
Wednesday, July 17, 2024
TenX, IPO, Intellia Therapeutics, News, Therapy, CVC, PTCL, Research, IBD, MD Anderson Cancer Center, Diphtheria, Jazz Pharmaceuticals, Peripheral T-cell lymphoma, Sickle cell disease, FDA, COVID-19, Ethanol, Epilepsy, MLT, EF Hutton, Patient, University, Interleukin, Standard of care, Minocycline, Gene editing, Relative strength, Vertex Pharmaceuticals, Jazz, CRISPR Therapeutics, Obesity, Biotechnology, Sleep, CTCL, PDUFA, Vertex, Ionis Pharmaceuticals, Health, CRISPR, Letter, Pharmaceutical industry

Second, on a more fundamental level, new technologies and launches in new therapeutic areas are poised to boost productivity and drive biotech performance."

Key Points: 
  • Second, on a more fundamental level, new technologies and launches in new therapeutic areas are poised to boost productivity and drive biotech performance."
  • Looking at some of Morningstar's top biotech picks , they report, "These were the most undervalued biotech stocks that Morningstar's analysts cover as of June 5, 2024: Intellia Therapeutics ,Crispr Therapeutics ,Royalty Pharma ,Jazz Pharmaceuticals, Moderna, Ionis Pharmaceuticals, and Incyte.
  • TimesSquare Capital US Small Cap Growth Strategy highlighted stocks like Krystal Biotech, Inc., in the first quarter 2024 investor letter.
  • Biotech stocks took center stage during Covid and as the sector continues to reinvent the future of health, they are still on the must watch list for analysts searching for an undervalued opportunity,

Enlaza Therapeutics Appoints Jeffrey Leiden, M.D., Ph.D., as a Key Advisor

Retrieved on: 
Tuesday, June 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Sickle cell disease, Pathology, Drug discovery, University, CRISPR Therapeutics, Cardiology, CRISPR, Public health, SCD, Therapy, Biology, American Academy, Beta thalassemia, Acquisition, Laboratory, Harvard Medical School, Elkan, Disease, National academy, Science, Cystic fibrosis, Patient, Vertex Pharmaceuticals, TDT, Abbott Laboratories, Semma, Doctor of Philosophy, Pharmaceutical industry

Enlaza Therapeutics , the first covalent biologic platform company, today announced the appointment of Dr. Jeffrey Leiden, Executive Chairperson of Vertex Pharmaceuticals, as a key advisor to the company.

Key Points: 
  • Enlaza Therapeutics , the first covalent biologic platform company, today announced the appointment of Dr. Jeffrey Leiden, Executive Chairperson of Vertex Pharmaceuticals, as a key advisor to the company.
  • He has dedicated his career to developing important first-in-class medicines from novel breakthrough technologies that have helped millions of people with serious diseases,” said Sergio Duron, Ph.D., CEO of Enlaza Therapeutics.
  • “With our War-Lock platform, we can create covalent protein drugs with the potential to improve treatments for many diseases.
  • He is an elected member of both the American Academy of Arts and Sciences and the National Academy of Medicine.

Pharma Oncology Development Veteran Krista McKerracher Named Chairperson of the Board for Genialis

Retrieved on: 
Wednesday, June 12, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Science, Biotechnology, Health, Multimedia, Patient, Gene editing, Artificial intelligence, Standard of care, Doctor of Philosophy, RNA, CRISPR Therapeutics, Therapy, Genomics, Hope, Biomarker, B cell, MBA, York University, Algorithm, Johnson & Johnson, University, Live Lounge, Medicine, Bachelor of Science, Drug development, HBF, Hemoglobinopathy, Biodata, Festival, Neoplasm, CRISPR, BBC, Cancer, Chairperson, Management

Genialis , the RNA-biomarker company, today announced the appointment of Krista McKerracher as Chairperson of the Board of Directors.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced the appointment of Krista McKerracher as Chairperson of the Board of Directors.
  • McKerracher is a seasoned biopharmaceutical leader passionate about bringing new medicines to patients with life-threatening diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240610583245/en/
    Genialis Introduces Krista McKerracher as Chairperson of the Board.
  • To schedule a meeting at the Frontline Genomcis event, or learn more about Genialis biomarker programs, please visit https://www.genialis.com/rna-biomarkers or email [email protected]

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 29, 2024
Therapy, CRISPR Therapeutics, CRSP

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.

Key Points: 
  • ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.
  • A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events .
  • A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, May 23, 2024
Partnership, Mechanical engineering, Patient, Inflammation, Faculty, Vertex, Rheumatology, Vertex Pharmaceuticals, Princeton University, McGill University, Immunology, McKinsey & Company, Eosinophilic esophagitis, Internal medicine, Therapy, Drug development, CRISPR Therapeutics, MIT, Dermatology, Hemoglobinopathy, Harvard University, NewYork-Presbyterian Hospital, Harvard Medical School, International development, Nursing care plan, Hospital, Chronic obstructive pulmonary disease, Dupilumab, CRISPR, Biotechnology, AstraZeneca, CRSP, NIH, Gastroenterology, Pharmaceutical industry

ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company also announced the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer, effective as of May 23, 2024. She currently serves as the Company’s Senior Vice President and Head of Programs & Portfolio Management.

Key Points: 
  • “I’m thrilled to welcome a transformational leader of Naimish’s caliber to the executive team at CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics.
  • Since joining CRISPR Therapeutics in 2019, Julie has been a valuable member of the leadership team and has led several important and impactful cross-functional initiatives including our collaboration with Vertex.
  • Julianne Bruno, M.B.A., has served as Senior Vice President and Head of Programs & Portfolio Management at CRISPR Therapeutics since March 2023.
  • In addition, she has been responsible for program leadership of our immuno-oncology assets and the program management function across our franchises.

Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer

Retrieved on: 
Monday, May 13, 2024
Research, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Patient, Biology, Stem cell, Burns, University, IND, Therapy, Disease, CRISPR Therapeutics, Purdue University, System, Medicine, Regenerative medicine, Genzyme, RNA, CRISPR, Master of Science, Management

Ensoma, a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the appointment of Jim Burns, Ph.D., as chief executive officer and a member of the company’s board of directors.

Key Points: 
  • Ensoma, a genomic medicines company advancing the future of medicine through precision one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the appointment of Jim Burns, Ph.D., as chief executive officer and a member of the company’s board of directors.
  • “Jim Burns is an accomplished biotechnology executive who joins Ensoma at a critical and exciting time for the company as we advance our first program through IND-enabling studies,” said Paula Soteropoulos, chairman of the board and interim CEO of Ensoma.
  • Before that, he was CEO of Casebia Therapeutics, which is now part of CRISPR Therapeutics.
  • Dr. Burns is a member of the U.S. National Academy of Engineering and a past board member of MassBio and the Alliance for Regenerative Medicine.